What is Raymond James’ Estimate for TSE:MDP FY2025 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Raymond James boosted their FY2025 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Monday, February 3rd. Raymond James analyst M. Freeman now forecasts that the company will earn $0.07 per share for the year, up from their previous forecast of $0.03. Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.51) EPS, FY2028 earnings at $2.10 EPS and FY2029 earnings at $3.05 EPS.

Several other brokerages have also issued reports on MDP. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Ventum Financial increased their price target on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research report on Thursday, January 30th. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a report on Thursday, January 30th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and five have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and a consensus price target of C$6.13.

Medexus Pharmaceuticals Stock Performance

TSE MDP opened at C$3.79 on Thursday. The stock’s 50 day moving average price is C$3.52 and its two-hundred day moving average price is C$2.82. The stock has a market capitalization of C$92.97 million, a price-to-earnings ratio of 75.80 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.